Additional content of the national risk-based control plans and randomised surveillance plan
Article 7
1. The national risk-based control plans, referred to in Articles 4 and 6, and national randomised surveillance plan, referred to in Article 5, shall specify the following information: (a) the details on species to be sampled and on place of sampling; (b) information on the national legislation on the use of pharmacologically active substances and, in particular, on their prohibition or authorisation, distribution and placing on the market and the rules governing their administration, in so far as such legislation is not harmonised; (c) information about the competent authorities responsible for the implementation of the plans; (d) the type of follow-up measures taken by the competent authorities with regard to animals or products of animal origin in which non-compliant residues have been detected in the previous years 2. The national risk based control plans referred to in Articles 4 and 6 shall, in addition to the information specified in paragraph 1, provide the following: (a) a justification for the selected substances, species, products and matrices included in the plans on the basis of the criteria listed in Annexes II and VI to Delegated Regulation (EU) 2022/1644, including a justification on how the criteria listed in those Annexes were taken into account, even if no changes were made compared to the plan of the previous year; (b) a justification on how information from an overview of the non-compliances in the relevant Member State of the previous three calendar years provided by EFSA was taken into account for optimising the plan. Member States do not need submit information already provided in the general part of the MANCP or described in Union legislation according to Article 110(2) of Regulation (EU) 2017/625.